Market Overview:
The global nausea and vomiting treatment market is expected to grow at a CAGR of 5.5% from 2018 to 2030. The market was valued at USD 2,362.8 million in 2018 and is projected to reach USD 3,471.1 million by 2030. Serotonin receptor antagonist had the biggest market share of 61% in 2018 while neurokinin NK1 receptor antagonist had the second-biggest share of 18%. In terms of application, CINV is the greatest segment of Nausea And Vomiting Treatment application, with a share of 49% in 2018. North America has been leading the global nausea and vomiting treatment market since 2017 and is expected to continue its dominance during the forecast period as well (2018-2030).
Product Definition:
Nausea and vomiting are common symptoms of many diseases and conditions. Nausea is a sensation that often precedes vomiting. It is an uneasiness or discomfort in the stomach that may lead to vomiting. Vomiting, also called emesis, is the act of throwing up or regurgitating food and/or liquid from the stomach.
Serotonin Receptor Antagonist:
According to the National Institute of Mental Health, approximately 15.0 million adults in the U.S. have been diagnosed with major depression in 2016 and 7.0 million have been treated with medication only to discover that this is not a permanent cure but rather a chronic condition that requires continuous monitoring and management which leads to high demand for various anti-depressant drugs over the counter (OTC) medications used for its treatment such as selective serotonin receptor antagonists (SSRIs).
Neurokinin NK1 Receptor Antagonist:
Neurokinin NK1 receptor antagonist is a type of drug that works by blocking the action of neurokinin (NKR) receptors, which are present on nerve cells in the brain stem. Blocking these receptors prevents nausea and vomiting.
Application Insights:
PONV is the second-largest application of nausea and vomiting treatments, with a share of 30.4% in 2018. The rising prevalence of PONV due to various factors such as changes in climate, diet and alcohol intake is anticipated to boost the demand for these drugs over the forecast period., motion sicknessness is expected to be one of the fastest growing segments during the forecast period owing to increasing use in cruise ships and long haul flight., pregnancy related nausea and vomiting has become a common occurrence among women who are pregnant for 1st time or 2nd time. This has increased awareness about treatment options which may help drive growth., others include anxiety related nausea & vomiting caused due largely by environmental factors such as food allergies that may require medical consultation before treating with medication., CINV segment accounted for 49% share in 2018 owing largely on account increase incidence globally since last few years especially after 50 years old age group where prevalence rate increases exponentially thus driving market growth over next seven years.
Regional Analysis:
North America dominated the global market in 2018. This can be attributed to the high prevalence of functional gastrointestinal disorders, increasing awareness about available treatment options, and availability of highly effective drugs. Moreover, presence of key pharmaceutical companies that are engaged in strategic initiatives for development and commercialization of novel anti-nausea/vomiting drugs is also expected to drive regional growth over the forecast period.
Asia Pacific region is anticipated to witness lucrative CAGR during the forecast period owing to rising geriatric population base coupled with increasing incidence rates for chronic diseases such as cancer., diabetes., Parkinson’s disease (PD), multiple sclerosis (MS) & other neurological disorders which result in PONV or nausea & vomiting attacks The prevalence rate for these conditions ranges from 7% - 10% among Asian population which is higher than that observed among white people (3%). These factors are contributing towards increased demand for nausea and vomiting treatments among patients from Asia Pacific region.
Growth Factors:
- Rising incidence of nausea and vomiting across the globe
- Increasing awareness about various nausea and vomiting treatments available in the market
- Growing demand for minimally invasive procedures for treating nausea and vomiting
- Technological advancements in the field of nausea and vomiting treatment therapies
- Rising number of clinical studies on new drugs for treating nausea and vomiting
Scope Of The Report
Report Attributes
Report Details
Report Title
Nausea And Vomiting Treatment Market Research Report
By Type
Serotonin Receptor Antagonist, Neurokinin NK1 Receptor Antagonist, Other, Serotonin receptor antagonist had the biggest market share of 61% in 2018., Nausea And Vomiting Treatmen
By Application
CINV, PONV, Motion Sickness, Pregnancy, Others, CINV is the greatest segment of Nausea And Vomiting Treatment application, with a share of 49% in 2018.
By Companies
Merck & Co. Inc., Helsinn Group, Unimed Pharmaceuticals (AbbVie Inc.), Kyowa Kirin, Sanofi, Qilu Pharma, Teva Pharmaceutical Industries Ltd., Taiji group, Novartis, Heron Therapeutics, Atnahs Pharma UK Limited, Mylan, Duchesnay, Tesaro, Nausea And Vomiting Treatmen
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
239
Number of Tables & Figures
168
Customization Available
Yes, the report can be customized as per your need.
Global Nausea And Vomiting Treatment Market Report Segments:
The global Nausea And Vomiting Treatment market is segmented on the basis of:
Types
Serotonin Receptor Antagonist, Neurokinin NK1 Receptor Antagonist, Other, Serotonin receptor antagonist had the biggest market share of 61% in 2018., Nausea And Vomiting Treatmen
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
CINV, PONV, Motion Sickness, Pregnancy, Others, CINV is the greatest segment of Nausea And Vomiting Treatment application, with a share of 49% in 2018.
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Merck & Co. Inc.
- Helsinn Group
- Unimed Pharmaceuticals (AbbVie Inc.)
- Kyowa Kirin
- Sanofi
- Qilu Pharma
- Teva Pharmaceutical Industries Ltd.
- Taiji group
- Novartis
- Heron Therapeutics
- Atnahs Pharma UK Limited
- Mylan
- Duchesnay
- Tesaro
- Nausea And Vomiting Treatmen
Highlights of The Nausea And Vomiting Treatment Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Serotonin Receptor Antagonist
- Neurokinin NK1 Receptor Antagonist
- Other
- Serotonin receptor antagonist had the biggest market share of 61% in 2018.
- Nausea And Vomiting Treatmen
- By Application:
- CINV
- PONV
- Motion Sickness
- Pregnancy
- Others
- CINV is the greatest segment of Nausea And Vomiting Treatment application, with a share of 49% in 2018.
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Nausea And Vomiting Treatment Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Nausea and vomiting treatment is a combination of medications and lifestyle changes that are used to reduce the frequency, intensity, or both of nausea and vomiting. Treatment may also include rest, fluids, food replacement therapy, anti-nausea medications (such as prochlorperazine), and pain relief.
Some of the major players in the nausea and vomiting treatment market are Merck & Co. Inc., Helsinn Group, Unimed Pharmaceuticals (AbbVie Inc.), Kyowa Kirin, Sanofi, Qilu Pharma, Teva Pharmaceutical Industries Ltd., Taiji group, Novartis, Heron Therapeutics, Atnahs Pharma UK Limited, Mylan, Duchesnay, Tesaro, Nausea And Vomiting Treatmen.
The nausea and vomiting treatment market is expected to grow at a compound annual growth rate of 5.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Nausea And Vomiting Treatment Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Nausea And Vomiting Treatment Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Nausea And Vomiting Treatment Market - Supply Chain
4.5. Global Nausea And Vomiting Treatment Market Forecast
4.5.1. Nausea And Vomiting Treatment Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Nausea And Vomiting Treatment Market Size (000 Units) and Y-o-Y Growth
4.5.3. Nausea And Vomiting Treatment Market Absolute $ Opportunity
5. Global Nausea And Vomiting Treatment Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Nausea And Vomiting Treatment Market Size and Volume Forecast by Type
5.3.1. Serotonin Receptor Antagonist
5.3.2. Neurokinin NK1 Receptor Antagonist
5.3.3. Other
5.3.4. Serotonin receptor antagonist had the biggest market share of 61% in 2018.
5.3.5. Nausea And Vomiting Treatmen
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Nausea And Vomiting Treatment Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Nausea And Vomiting Treatment Market Size and Volume Forecast by Application
6.3.1. CINV
6.3.2. PONV
6.3.3. Motion Sickness
6.3.4. Pregnancy
6.3.5. Others
6.3.6. CINV is the greatest segment of Nausea And Vomiting Treatment application, with a share of 49% in 2018.
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Nausea And Vomiting Treatment Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Nausea And Vomiting Treatment Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Nausea And Vomiting Treatment Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Nausea And Vomiting Treatment Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Nausea And Vomiting Treatment Demand Share Forecast, 2019-2026
9. North America Nausea And Vomiting Treatment Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Nausea And Vomiting Treatment Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Nausea And Vomiting Treatment Market Size and Volume Forecast by Application
9.4.1. CINV
9.4.2. PONV
9.4.3. Motion Sickness
9.4.4. Pregnancy
9.4.5. Others
9.4.6. CINV is the greatest segment of Nausea And Vomiting Treatment application, with a share of 49% in 2018.
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Nausea And Vomiting Treatment Market Size and Volume Forecast by Type
9.7.1. Serotonin Receptor Antagonist
9.7.2. Neurokinin NK1 Receptor Antagonist
9.7.3. Other
9.7.4. Serotonin receptor antagonist had the biggest market share of 61% in 2018.
9.7.5. Nausea And Vomiting Treatmen
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Nausea And Vomiting Treatment Demand Share Forecast, 2019-2026
10. Latin America Nausea And Vomiting Treatment Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Nausea And Vomiting Treatment Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Nausea And Vomiting Treatment Market Size and Volume Forecast by Application
10.4.1. CINV
10.4.2. PONV
10.4.3. Motion Sickness
10.4.4. Pregnancy
10.4.5. Others
10.4.6. CINV is the greatest segment of Nausea And Vomiting Treatment application, with a share of 49% in 2018.
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Nausea And Vomiting Treatment Market Size and Volume Forecast by Type
10.7.1. Serotonin Receptor Antagonist
10.7.2. Neurokinin NK1 Receptor Antagonist
10.7.3. Other
10.7.4. Serotonin receptor antagonist had the biggest market share of 61% in 2018.
10.7.5. Nausea And Vomiting Treatmen
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Nausea And Vomiting Treatment Demand Share Forecast, 2019-2026
11. Europe Nausea And Vomiting Treatment Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Nausea And Vomiting Treatment Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Nausea And Vomiting Treatment Market Size and Volume Forecast by Application
11.4.1. CINV
11.4.2. PONV
11.4.3. Motion Sickness
11.4.4. Pregnancy
11.4.5. Others
11.4.6. CINV is the greatest segment of Nausea And Vomiting Treatment application, with a share of 49% in 2018.
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Nausea And Vomiting Treatment Market Size and Vlume Forecast by Type
11.7.1. Serotonin Receptor Antagonist
11.7.2. Neurokinin NK1 Receptor Antagonist
11.7.3. Other
11.7.4. Serotonin receptor antagonist had the biggest market share of 61% in 2018.
11.7.5. Nausea And Vomiting Treatmen
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Nausea And Vomiting Treatment Demand Share, 2019-2026
12. Asia Pacific Nausea And Vomiting Treatment Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Nausea And Vomiting Treatment Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Nausea And Vomiting Treatment Market Size and Volume Forecast by Application
12.4.1. CINV
12.4.2. PONV
12.4.3. Motion Sickness
12.4.4. Pregnancy
12.4.5. Others
12.4.6. CINV is the greatest segment of Nausea And Vomiting Treatment application, with a share of 49% in 2018.
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Nausea And Vomiting Treatment Market Size and Volume Forecast by Type
12.7.1. Serotonin Receptor Antagonist
12.7.2. Neurokinin NK1 Receptor Antagonist
12.7.3. Other
12.7.4. Serotonin receptor antagonist had the biggest market share of 61% in 2018.
12.7.5. Nausea And Vomiting Treatmen
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Nausea And Vomiting Treatment Demand Share, 2019-2026
13. Middle East & Africa Nausea And Vomiting Treatment Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Nausea And Vomiting Treatment Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Nausea And Vomiting Treatment Market Size and Volume Forecast by Application
13.4.1. CINV
13.4.2. PONV
13.4.3. Motion Sickness
13.4.4. Pregnancy
13.4.5. Others
13.4.6. CINV is the greatest segment of Nausea And Vomiting Treatment application, with a share of 49% in 2018.
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Nausea And Vomiting Treatment Market Size and Volume Forecast by Type
13.7.1. Serotonin Receptor Antagonist
13.7.2. Neurokinin NK1 Receptor Antagonist
13.7.3. Other
13.7.4. Serotonin receptor antagonist had the biggest market share of 61% in 2018.
13.7.5. Nausea And Vomiting Treatmen
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Nausea And Vomiting Treatment Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Nausea And Vomiting Treatment Market: Market Share Analysis
14.2. Nausea And Vomiting Treatment Distributors and Customers
14.3. Nausea And Vomiting Treatment Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Merck & Co. Inc.
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Helsinn Group
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Unimed Pharmaceuticals (AbbVie Inc.)
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Kyowa Kirin
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Sanofi
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Qilu Pharma
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Teva Pharmaceutical Industries Ltd.
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Taiji group
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Novartis
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Heron Therapeutics
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. Atnahs Pharma UK Limited
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. Mylan
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. Duchesnay
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. Tesaro
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. Nausea And Vomiting Treatmen
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
&n